IP Library Granted Patent US 12,303,429
Granted Patent B2
US 12,303,429 · App. 18/366,376 · Granted May 20, 2025

Method and device for treating eye disease

Inventors: Brandon Wei-Hsiang Kao (Placentia, CA); Adarsh Narayan Battu (Fremont, CA); Rui Jing Jiang (Lexington, MA)
Assignee: Avisi Technologies, Inc.
A61F9/00781A61F2220/0016A61F2230/0004A61F2230/0019A61F2230/0021A61F2230/0023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,303,429
App. No.
18/366,376
Granted
May 20, 2025
Kind
B2
Abstract

A device for lowering intraocular pressure is disclosed herein. In an example, the device includes a continuous plate structure that enables aqueous humor to flow from a first end to a second end. The first end has a maximum width that is narrower than a maximum width of the second end. The continuous plate structure includes an uppermost surface opposite a lowermost surface, the uppermost surface including a plurality of open cells. The continuous plate structure also includes a fluid pathway including a plurality of open channels formed into the lowermost surface. The open channels are configured in an intersecting grid pattern extending from the first end to the second end of the continuous plate structure. The open channels provide for the flow of aqueous humor, thereby reducing intraocular pressure.

Claims (16)

1. An implantable apparatus for reducing intraocular pressure within an eye, the apparatus comprising:

a continuous plate structure sized and configured to enable aqueous humor to flow from a first end to a second end, the continuous plate structure comprising:

a main body portion having a proximal end opposite a distal end, the main body portion having a maximum length as measured from a distance between the proximal end and the distal end of the main body portion;

an extension portion having a proximal end opposite a distal end, the extension portion having a maximum length as measured from a distance between the proximal end and the distal end of the extension portion, wherein a longitudinal axis intersects the proximal and distal ends of both the main body portion and the extension portion and the proximal end of the extension portion extends from the distal end of the main body portion;

an uppermost surface opposite a lowermost surface, the uppermost surface including a plurality of open cells; and

a fluid pathway including a plurality of open channels formed into the lowermost surface, the plurality of open channels configured in an intersecting grid pattern extending from the first end to the second end,

wherein the main body portion has a maximum width measured in a direction normal to the longitudinal axis, and the extension portion has a maximum width measured in a direction normal to the longitudinal axis, wherein the maximum width of the main body portion is greater than the maximum width of the extension portion,

wherein the first end of the continuous plate structure is sized and configured to be inserted into an anterior chamber of the eye and the second end of the continuous plate structure is sized and configured to be inserted into at least one of an uveoscleral outflow pathway, Schlemm's canal, a collector channel, a supraciliary space, a trabecular meshwork, a subconjunctival space, or a suprachoroidal space of the eye, and

wherein the continuous plate structure is configured to enable aqueous humor to flow along the fluid pathway, from the first end to the second end, thereby reducing intraocular pressure within the eye.

2. The apparatus of claim 1 , wherein the intersecting grid pattern includes a hexagonal grid pattern.

3. The apparatus of claim 1 , wherein the continuous plate structure is configured to be implanted such that the uppermost surface is configured to face a conjunctiva of the eye and the lowermost surface is configured to face a sclera of the eye.

4. The apparatus of claim 1 , wherein the first end of the continuous plate structure is configured to be inserted into the anterior chamber of the eye and the second end of the continuous plate structure is configured to be inserted between a superior rectus muscle and an inferior rectus muscle.

5. The apparatus of claim 1 , wherein the continuous plate structure is formed from at least one of alumina (Al 2 O 3 ), silicon nitride (Si x N y ), silica (SiO 2 ), hafnium oxide (HfO 2 ), titanium nitride (TiN x ), or titanium carbide (TiC).

6. The apparatus of claim 1 , wherein the continuous plate structure is configured to fold at least 90° without fracturing.

7. The apparatus of claim 1 , wherein the continuous plate structure has a thickness between 1 nanometer (nm) and 1,000 nm.

8. The apparatus of claim 1 , wherein a ratio of the maximum width of the main body portion to the maximum width of the extension portion ranges from about 1.1:1 to about 4:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2023
From: KAO, BRANDON WEI-HSIANG; BATTU, ADARSH NARAYAN; JIANG, RUI JING
To: AVISI TECHNOLOGIES, INC.
Reel/Frame 064520/0799 →
Continuity (4)
Continuation 16254765 · Jan 23, 2019
Provisional Application 62794139 · Jan 18, 2019
Provisional Application 62620922 · Jan 23, 2018
Related Publication 20230372152A1 · Nov 23, 2023
References Cited (26)
US 4521210A · Wong · 1985 [cited by applicant]
US 5433701A · Rubinstein · 1995 [cited by applicant]
US 5601094A · Reiss · 1997 [cited by applicant]
US 7207965B2 · Simon · 2007 [cited by examiner]
US 20040254521A1 · Simon · 2004 [cited by applicant]
US 20040260227A1 · Lisk et al. · 2004 [cited by applicant]
US 20050184004A1 · Rodgers et al. · 2005 [cited by applicant]
US 20050267398A1 · Protopsaltis et al. · 2005 [cited by applicant]
US 20050283108A1 · Savage · 2005 [cited by applicant]
US 20090177138A1 · Brown et al. · 2009 [cited by applicant]
US 20100249691A1 · Van Der Mooren et al. · 2010 [cited by applicant]
US 20130150773A1 · Nissan et al. · 2013 [cited by applicant]
US 20150018746A1 · Hattenbach · 2015 [cited by applicant]
US 20150230983A1 · Johnson · 2015 [cited by applicant]
US 20170020730A1 · Chew et al. · 2017 [cited by applicant]
US 20200173019A1 · Bargatin et al. · 2020 [cited by applicant]
JP 2002521145A · 2002 [cited by applicant]
JP 2017506139A · 2017 [cited by applicant]
JP 2017519592A · 2021 [cited by applicant]
WO 2010111528A2 · 2010 [cited by applicant]
WO 2016044173A1 · 2016 [cited by applicant]
WO 2016140334A1 · 2018 [cited by applicant]
WO WO2018156687A1 · 2018 [cited by examiner]
International Search Report and Written Opinion from Application No. PCT/US2019/14663, Dated Apr. 23, 2019, in 12 pages. [cited by applicant]
Office Action for Japanese Application No. 2020-561580, dated Feb. 21, 2023, in 11 pages. [cited by applicant]
Supplementary European Search Report, Application No. PCT/US2019/014663, Dated Sep. 16, 2021 in 7 pages. [cited by applicant]